Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Core Viewpoint - Actinium Pharmaceuticals, Inc. is under investigation for potential claims following a significant stock drop after the FDA's decision regarding its Biologics License Application for Iomab-B [2][3]. Investigation Details - On August 5, 2024, Actinium announced that the FDA deemed the Phase 3 SIERRA trial insufficient to support a BLA filing for Iomab-B, despite achieving a statistically significant primary endpoint [2]. - Following this announcement, Actinium's stock plummeted nearly 60% on the same day [2]. Next Steps - Investors who have information related to the investigation or who purchased Actinium securities are encouraged to assist by visiting the firm's website or contacting the firm's representatives [3]. Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and attorney fees if successful in the case [4]. Firm Background - Bronstein, Gewirtz & Grossman, LLC is a recognized firm specializing in representing investors in securities fraud class actions and has recovered hundreds of millions of dollars for investors across the nation [5].